Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Incyte Corporation
  6. Company
    INCY   US45337C1027

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Incyte Corporation
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Number of employees : 1 773 people.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Proprietary Therapeutics1,77582.2%2,06977.6% +16.55%
Product Royalty306.3414.2%392.9714.7% +28.28%
Milestone and Contract77.503.6%205.007.7% +164.52%
Sales per region
2020
USD (in Million)%
United States1,93872.7%
Global597.9722.4%
Europe105.003.9%
China and Taiwan25.881%
Managers
NameAgeSinceTitle
Hervé Hoppenot602015Chairman, President & Chief Executive Officer
Christiana Stamoulis492019Chief Financial Officer & Executive Vice President
Steven Stein532016Chief Medical Officer & Executive Vice President
Dashyant Dhanak592018Chief Scientific Officer & Executive VP
Paul Friedman772014Independent Director
Julian Charles Baker53-Lead Independent Director
Wendy L. Dixon, Dr.642011Independent Director
Jean-Jacques Bienaimé662015Independent Director
Paul J. Clancy582015Independent Director
Jacqualyn A. Fouse, Dr.582017Independent Director
Members of the board
NameAgeSinceTitle
Hervé Hoppenot602015Chairman, President & Chief Executive Officer
Paul Friedman772014Independent Director
Julian Charles Baker53-Lead Independent Director
Wendy L. Dixon, Dr.642011Independent Director
Jean-Jacques Bienaimé662015Independent Director
Paul J. Clancy582015Independent Director
Jacqualyn A. Fouse, Dr.582017Independent Director
Edmund P. Harrigan, Dr.672019Independent Director
Katherine A. High, Dr.682020Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 219,923,477 216,838,843 98.6% 0 0.0% 98.6%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 32,594,682 14.8%
Baker Bros. Advisors LP 32,479,865 14.8%
The Vanguard Group, Inc. 19,312,859 8.78%
Wellington Management Co. LLP 13,499,976 6.14%
SSgA Funds Management, Inc. 8,689,125 3.95%
Capital Research & Management Co. (International Investors) 6,789,813 3.09%
Renaissance Technologies LLC 5,889,133 2.68%
Columbia Wanger Asset Management LLC 5,295,000 2.41%
Durus Capital Management LLC 4,944,800 2.25%
BlackRock Fund Advisors 4,468,074 2.03%
Holdings
NameEquities%Valuation
Merus N.V. (MRUS) 3,550,0009.31%74,159,500 USD
Agenus Inc. (AGEN) 14,062,2276.87%38,249,257 USD
Markets and indexes
-
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 500
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  INCY.O
- Datastream Code :  
Company contact information
Incyte Corporation
1801 Augustine Cut-Off
DE 19803 Wilmington, Delaware


Phone : +1 855 446 2983
Fax :
web site : http://investor.incyte.com
Sector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)
INCYTE CORPORATION-5.37%18 196
MODERNA, INC.53.63%64 284
LONZA GROUP AG1.05%46 978
IQVIA HOLDINGS INC.30.82%44 316
CELLTRION, INC.-25.77%30 699
SEAGEN INC.-20.36%24 694
CUREVAC N.V.23.84%21 497
HANGZHOU TIGERMED CONSULTING CO.,LTD-10.07%19 977
PHARMARON BEIJING CO., LTD.27.91%18 739
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.34.81%16 913
PPD, INC.34.72%16 198
BIO-TECHNE CORPORATION33.22%15 946
ALNYLAM PHARMACEUTICALS, INC.1.02%15 528
NOVAVAX, INC.57.83%12 780
ICON PUBLIC LIMITED COMPANY14.43%11 794
PRA HEALTH SCIENCES, INC.37.36%11 035
QIAGEN N.V.-9.86%10 897
UNITED THERAPEUTICS CORPORATION28.74%8 604
SYNEOS HEALTH, INC.21.56%8 445
CRISPR THERAPEUTICS AG-29.66%8 171
ABCELLERA BIOLOGICS INC.-28.68%7 776